← Back to patent-cliff list
Oxipurinol (XORTX Therapeutics)
Tier C — Watch / tradeOxipurinol (XORTX Therapeutics)
Xortx Therapeutics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：XO
Brand：XORLO
Indications (approved)：Gout, 急性肾损伤, 多囊肾疾病
Regional status
US
Phase II
2023-04-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Oxipurinol (XORTX Therapeutics)?
Approved indications include: Gout, 急性肾损伤, 多囊肾疾病.
When does the Oxipurinol (XORTX Therapeutics) patent expire?
No public expiry year is available for Oxipurinol (XORTX Therapeutics) yet; this page updates once verified.
How do I get a quote for Oxipurinol (XORTX Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29